How many institutions held INDP - Indaptus Therapeutics, Inc. - Common Stock, $0.01 par value in Q3 2021?

9 institutional investors reported INDP - Indaptus Therapeutics, Inc. - Common Stock, $0.01 par value for Q3 2021. Use the holders table for investor-level position and value details.

Indaptus Therapeutics, Inc. - Common Stock, $0.01 par value (INDP)

Q: What does CUSIP 45339J105 represent in this 13F holders report?

CUSIP 45339J105 is the security identifier for INDP - Indaptus Therapeutics, Inc. - Common Stock, $0.01 par value used to aggregate holder disclosures.

CUSIP: 45339J105

Q3 2021 13F Holders as of 30 Sep 2021

Type / Class: Equity / Common Stock, $0.01 par value
Shares outstanding: 113,183,288
Total 13F shares: 541,295
Share change: +541,295
Total reported value: $4,239,000
Price per share: $7.83
Number of holders: 9
Value change: +$4,239,000
Number of buys: 9

Quarterly Holders Quick Answers

What is CUSIP 45339J105?
CUSIP 45339J105 identifies INDP - Indaptus Therapeutics, Inc. - Common Stock, $0.01 par value in SEC institutional holdings data.

Need full ownership history?
Open the full security ownership history page.

Next holder-history checks

These links keep the next click tied to holder verification, nearby quarters, or outside-13F ownership context.

Back to full security ownership history for the broader multi-quarter picture.
Latest 13F filings for newly reported positions across managers.
Latest Schedule 13D/13G reports for ownership changes outside the 13F cadence.
SEC investors directory for manager drilldown.

Explore More Reporting Periods

Jump to adjacent filing periods for faster comparison and easier crawl discovery.

Newer quarter: Q4 2021

Recent filing periods for CUSIP 45339J105:

Q2 2025 Q1 2025 Q4 2024 Q3 2024 Q2 2024 Q1 2024 Q4 2023 Q3 2023

Top shareholders of INDP - Indaptus Therapeutics, Inc. - Common Stock, $0.01 par value (13F + 13D/G + 3/4/5)

Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.

Methodology: rows are grouped by holder and ranked by the holder's primary source value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.

Holder	Source	Role / Reporting	Ownership %	Shares	Holdings Value	12M Net Δ	As of	Details
Hoonmo Lee	3/4/5	Director	— mixed-class rows	708,272 mixed-class rows	$1,626,157	—	04 Aug 2021	3/4/5

Institutional Holders of Indaptus Therapeutics, Inc. - Common Stock, $0.01 par value (INDP) as of Q3 2021

As of 30 Sep 2021, Indaptus Therapeutics, Inc. - Common Stock, $0.01 par value (INDP) was held by 9 institutional shareholders that filed Form 13F with the SEC. Together, they reported ownership of 541,295 shares. The largest 9 holders included ARMISTICE CAPITAL, LLC, VANGUARD GROUP INC, GEODE CAPITAL MANAGEMENT, LLC, INVESTMENT HOUSE LLC, CITADEL ADVISORS LLC, MARSHALL WACE, LLP, Harel Insurance Investments & Financial Services Ltd., MORGAN STANLEY, and UBS Group AG. This page lists 9 institutional shareholders reporting positions in this security for the Q3 2021 filing period.

Investor	Option	Weight %	Change %	Value $	* Price	Shares	Share Change	Activity	Report Period

Compare Q3 2021 vs Q1 2025 Across Filers

Q1 2025 holders

Q3 2021 holders

Holder diff

-8

Investor	Q1 2025 Shares	Q3 2021 Shares	Share Diff	Share Chg %	Q1 2025 Value $	Q3 2021 Value $	Value Diff $	Value Chg %

Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).

Quarterly Holders Trend

Quarterly Value Trend

Quarterly Shares Trend

* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.